Topic Editors

Department of Experimental Pathology and Medicine, Mayo Clinic, Rochester, MN 55902, USA
Department of Pharmacology and Regenerative Medicine, Centre for Lung and Vascular Biology, College of Medicine, University of Illinois, Chicago, IL 60607, USA
Department of Biotechnology, Sahyadri Science College, Kuvempu University, Shimoga, India

Targeting Tumor Microvasculature of Malignant Metastatic Tumor

Abstract submission deadline
closed (25 September 2024)
Manuscript submission deadline
closed (25 November 2024)
Viewed by
2794

Topic Information

Dear Colleagues,

The formation of the blood supply system is an important step in the cancerous transformation of cells, resulting in the penetration of tumor cells into the neighboring tissues and metastatic growth. Significant progress in the elucidation of mechanisms underlying tumor angiogenesis, along with the discovery of a great diversity of biomolecules involved in its regulation, have culminated in the development of a radically novel approach to antitumor therapy based on the search for effective inhibitors of tumor angiogenesis. Angiogenesis inhibitors target the neovascular development that is hypothesized as triggering tumor growth. The inhibitors that are involved in the search for the anti-angiogenesis process can be divided into five categories, based on their target activity: 1) drugs that block matrix breakdown; 2) drugs that inhibit endothelial cells directly; 3) drugs that block angiogenesis activators; 4) drugs that inhibit endothelial cell integrins or survival signaling; and 5) drugs with a currently unknown mechanism of action. In recent years, a great deal of research has been focused on the search for novel anti angiogenic drugs in the area of endogenous peptides, small organic molecules, microRNAs, cytotoxic molecules and so on. In this vein, we welcome original research, cutting-edge reviews and clinical trials. These should related, but not limited, to the aspects of the field listed: identification of small molecules, endogenous peptides, small organic molecules, microRNAs, cytotoxic molecules, antibody-drug conjugates, synergistic combination therapy, synthetic and natural biomolecules, nanoparticles and repurposing drugs, etc., against regulation of tumor angiogenesis and metastasis towards the identification of new anti-angiogenic drugs.

Dr. Prabhu Thirusangu
Dr. Vigneshwaran Vellingiri
Dr. Prabhakar Thippegowda
Topic Editors

Keywords

  • anti-angiogenesis
  • tumor vasculature
  • metastasis
  • VEGF
  • angiogenesis inhibitors
  • anti-cancer

Participating Journals

Journal Name Impact Factor CiteScore Launched Year First Decision (median) APC
Cancers
cancers
4.5 8.0 2009 17.4 Days CHF 2900
Current Oncology
curroncol
2.8 3.3 1994 19.8 Days CHF 2200
Journal of Clinical Medicine
jcm
3.0 5.7 2012 16 Days CHF 2600
Journal of Personalized Medicine
jpm
- 4.1 2011 17.4 Days CHF 2600
Onco
onco
- - 2021 27.8 Days CHF 1000

Preprints.org is a multidisciplinary platform offering a preprint service designed to facilitate the early sharing of your research. It supports and empowers your research journey from the very beginning.

MDPI Topics is collaborating with Preprints.org and has established a direct connection between MDPI journals and the platform. Authors are encouraged to take advantage of this opportunity by posting their preprints at Preprints.org prior to publication:

  1. Share your research immediately: disseminate your ideas prior to publication and establish priority for your work.
  2. Safeguard your intellectual contribution: Protect your ideas with a time-stamped preprint that serves as proof of your research timeline.
  3. Boost visibility and impact: Increase the reach and influence of your research by making it accessible to a global audience.
  4. Gain early feedback: Receive valuable input and insights from peers before submitting to a journal.
  5. Ensure broad indexing: Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.

Published Papers

There is no accepted submissions to this Topic at this moment.
Back to TopTop